TLR9 and cancer: Reducing CpG content is practiced in gene therapy to limit inflammation and inactivation of gene expression through methylation, but it is not an obvious choice in the field of cancer treatments as CpG sequences have previously been used as adjuvants to cancer vaccines to stimulate the innate immune response through TLR9 activation32.